Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom. more
Time Frame | ADAP | Sector | S&P500 |
---|---|---|---|
1-Week Return | -5.54% | -3.72% | -0.05% |
1-Month Return | -0.61% | -1.85% | 2.75% |
3-Month Return | -43.68% | -11.4% | 7.4% |
6-Month Return | -36.88% | -4.41% | 10.47% |
1-Year Return | 31.57% | 4.13% | 27.57% |
3-Year Return | -83.62% | 0.3% | 29.56% |
5-Year Return | -55.53% | 36.62% | 89.3% |
10-Year Return | -96.3% | 106.81% | 206.09% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 1.12M | 3.96M | 6.15M | 27.15M | 60.28M | [{"date":"2019-12-31","value":1.86,"profit":true},{"date":"2020-12-31","value":6.57,"profit":true},{"date":"2021-12-31","value":10.2,"profit":true},{"date":"2022-12-31","value":45.04,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 97.50M | 91.57M | 111.09M | 127.73M | 9.86M | [{"date":"2019-12-31","value":76.34,"profit":true},{"date":"2020-12-31","value":71.69,"profit":true},{"date":"2021-12-31","value":86.98,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":7.72,"profit":true}] |
Gross Profit | (96.38M) | (87.61M) | (104.94M) | (100.58M) | 50.42M | [{"date":"2019-12-31","value":-191.14,"profit":false},{"date":"2020-12-31","value":-173.75,"profit":false},{"date":"2021-12-31","value":-208.12,"profit":false},{"date":"2022-12-31","value":-199.46,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | (8589.93%) | (2213.49%) | (1706.64%) | (370.48%) | 83.65% | [{"date":"2019-12-31","value":-10269.12,"profit":false},{"date":"2020-12-31","value":-2646.19,"profit":false},{"date":"2021-12-31","value":-2040.25,"profit":false},{"date":"2022-12-31","value":-442.9,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 140.89M | 137.36M | 168.40M | 191.11M | 200.02M | [{"date":"2019-12-31","value":70.44,"profit":true},{"date":"2020-12-31","value":68.67,"profit":true},{"date":"2021-12-31","value":84.19,"profit":true},{"date":"2022-12-31","value":95.55,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (139.77M) | (133.41M) | (162.25M) | (163.97M) | (138.04M) | [{"date":"2019-12-31","value":-13977000000,"profit":false},{"date":"2020-12-31","value":-13340500000,"profit":false},{"date":"2021-12-31","value":-16224600000,"profit":false},{"date":"2022-12-31","value":-16396500000,"profit":false},{"date":"2023-12-31","value":-13803800000,"profit":false}] |
Total Non-Operating Income/Expense | 5.62M | 5.79M | 6.04M | 251.00K | 31.47M | [{"date":"2019-12-31","value":17.86,"profit":true},{"date":"2020-12-31","value":18.39,"profit":true},{"date":"2021-12-31","value":19.2,"profit":true},{"date":"2022-12-31","value":0.8,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (136.92M) | (129.93M) | (157.30M) | (162.96M) | (112.53M) | [{"date":"2019-12-31","value":-13692300000,"profit":false},{"date":"2020-12-31","value":-12993000000,"profit":false},{"date":"2021-12-31","value":-15729900000,"profit":false},{"date":"2022-12-31","value":-16295900000,"profit":false},{"date":"2023-12-31","value":-11253500000,"profit":false}] |
Income Taxes | 242.00K | 162.00K | 791.00K | 2.50M | 1.34M | [{"date":"2019-12-31","value":9.69,"profit":true},{"date":"2020-12-31","value":6.49,"profit":true},{"date":"2021-12-31","value":31.68,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":53.5,"profit":true}] |
Income After Taxes | (137.16M) | (130.09M) | (158.09M) | (165.46M) | (113.87M) | [{"date":"2019-12-31","value":-13716500000,"profit":false},{"date":"2020-12-31","value":-13009200000,"profit":false},{"date":"2021-12-31","value":-15809000000,"profit":false},{"date":"2022-12-31","value":-16545600000,"profit":false},{"date":"2023-12-31","value":-11387100000,"profit":false}] |
Income From Continuous Operations | (137.16M) | (130.09M) | (158.09M) | (165.46M) | (113.87M) | [{"date":"2019-12-31","value":-13716500000,"profit":false},{"date":"2020-12-31","value":-13009200000,"profit":false},{"date":"2021-12-31","value":-15809000000,"profit":false},{"date":"2022-12-31","value":-16545600000,"profit":false},{"date":"2023-12-31","value":-11387100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (137.16M) | (130.09M) | (158.09M) | (165.46M) | (113.87M) | [{"date":"2019-12-31","value":-13716500000,"profit":false},{"date":"2020-12-31","value":-13009200000,"profit":false},{"date":"2021-12-31","value":-15809000000,"profit":false},{"date":"2022-12-31","value":-16545600000,"profit":false},{"date":"2023-12-31","value":-11387100000,"profit":false}] |
EPS (Diluted) | (1.31) | (0.96) | (1.02) | (1.00) | (0.66) | [{"date":"2019-12-31","value":-131,"profit":false},{"date":"2020-12-31","value":-96,"profit":false},{"date":"2021-12-31","value":-102,"profit":false},{"date":"2022-12-31","value":-100,"profit":false},{"date":"2023-12-31","value":-66,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ADAP | |
---|---|
Cash Ratio | 2.93 |
Current Ratio | 3.85 |
Quick Ratio | 3.82 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ADAP | |
---|---|
ROA (LTM) | -15.84% |
ROE (LTM) | -65.04% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ADAP | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.75 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.25 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ADAP | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 1.05 |
P/B | 1.86 |
Price/FCF | NM |
EV/R | 0.21 |
EV/Ebitda | NM |
PEG | 0.11 |
Adaptimmune Therapeutics Plc (ADAP) share price today is $0.5914
Yes, Indians can buy shares of Adaptimmune Therapeutics Plc (ADAP) on Vested. To buy Adaptimmune Therapeutics Plc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ADAP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Adaptimmune Therapeutics Plc (ADAP) via the Vested app. You can start investing in Adaptimmune Therapeutics Plc (ADAP) with a minimum investment of $1.
You can invest in shares of Adaptimmune Therapeutics Plc (ADAP) via Vested in three simple steps:
The 52-week high price of Adaptimmune Therapeutics Plc (ADAP) is $2.05. The 52-week low price of Adaptimmune Therapeutics Plc (ADAP) is $0.43.
The price-to-earnings (P/E) ratio of Adaptimmune Therapeutics Plc (ADAP) is
The price-to-book (P/B) ratio of Adaptimmune Therapeutics Plc (ADAP) is 1.86
The dividend yield of Adaptimmune Therapeutics Plc (ADAP) is 0.00%
The market capitalization of Adaptimmune Therapeutics Plc (ADAP) is $148.44M
The stock symbol (or ticker) of Adaptimmune Therapeutics Plc is ADAP